Jones Healthcare Group's Near-Term Emissions Reduction Targets Validated by the Science Based Targets Initiative
London, Ontario--(Newsfile Corp. - April 14, 2026) - Jones Healthcare Group's near-term greenhouse gas emissions reduction targets have been approved by the Science Based Targets initiative (SBTi), marking a significant step in the company's commitment to reducing emissions across its operations and broader value chain. As part of its validated targets, Jones commits to reduce absolute scope 1 and scope 2 greenhouse gas emissions 43.26% by 2030 from a 2023 base year. The company also c
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-14 10:00 AM EDT | Jones Healthcare Group
BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum
Vancouver, British Columbia--(Newsfile Corp. - April 14, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce that the Company has been selected as one of the top four innovators to present its liquid biopsy platform at the annual Canadian Thoracic Society (CTS) Research Forum. The presentation will take place in front of a panel of expe
Technologies, Biotechnologies, Soins de santé et hôpitaux
2026-04-14 8:30 AM EDT | BioMark Diagnostics, Inc.
Fotonara and PhantomOmics Announce Revolutionary Partnership and "Good for All Humans" Initiative to Transform Affordable Housing into Sovereign Health Guardians
Calgary, Alberta--(Newsfile Corp. - April 13, 2026) - Fotonara Inc., a pioneer in advanced manufacturing and sovereign smart building infrastructure, and PhantomOmics Inc., a visionary in proactive health technology, today announced a landmark global commercialization partnership. Together, the two Calgary-based tech innovators are launching the "Good for All Humans" initiative—a sweeping joint mission to make high-fidelity, preventative health monitoring a standard, low-cost uti
Technologies, Soins de santé et hôpitaux, Capteurs, Santé
2026-04-13 8:15 AM EDT | PhantomOmics Inc.
Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study
Toronto, Ontario--(Newsfile Corp. - April 13, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses has demonstrated a complete response of all animals treated with X-Ray-activated Rutherrin® in a preclinical animal model of M
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-04-13 7:00 AM EDT | Theralase Technologies Inc.
Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - April 13, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using it
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-13 7:00 AM EDT | Phio Pharmaceuticals Corp.
Voting Results of Cosmo's 2026 AGM
Dublin, Ireland--(Newsfile Corp. - April 10, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced that its shareholders approved all voting items at today’s Ordinary Annual General Meeting (AGM). A total of 10,354,065 ordinary shares of the share capital of Cosmo were represented at this general meeting of shareholders. These shares make up 59.02% of the total outstanding ordinary shares in the share capital of Cosmo as of the record
Soins de santé et hôpitaux, Santé
2026-04-10 9:16 AM EDT | Cosmo Pharmaceuticals N.V.
Theralase(R) Closes $CAN 2.66 Million Financing
Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has successfully closed both a non-brokered private placement offering ("Offering
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-04-10 7:00 AM EDT | Theralase Technologies Inc.
Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - April 9, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Robert Bitterman, Chief Executive Officer and Chairman of the Board, will present at the Centri Capital Conference on Tuesday, April 14, 2026, at Nasdaq Marketsite in New York City. The present
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-09 7:00 AM EDT | Phio Pharmaceuticals Corp.
MyndTec Inc. Announces Inability to Secure Financing, Cessation of Operations and Evaluation of Strategic Alternatives Including Insolvency Proceedings
Mississauga, Ontario--(Newsfile Corp. - April 8, 2026) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company") announces that it has been unable to secure the additional financing required to continue operations. As previously disclosed, the Company's operations during 2024 and 2025 were substantially funded by its principal shareholder, Jim Anderson, through his participation in successive private placement offerings. Mr. Anderson has confirmed that he will not be mak
Technologies, Soins de santé et hôpitaux, Santé
2026-04-08 12:17 PM EDT | MyndTec Inc.
Trenchant Technologies Capital Corp. Announces Unwinding of Previous Limitless Quantum Acquisition
Vancouver, British Columbia--(Newsfile Corp. - April 8, 2026) - Trenchant Technologies Capital Corp. (CSE: AITT) (OTCQB: AITTF) ("Trenchant" or the "Company") announces that it has entered into a share exchange agreement dated March 18, 2026 and fully executed on April 5, 2026, (the "Share Exchange Agreement") providing for the unwinding of the Company's previously announced acquisition of Limitless Quantum Computing Solutions Inc. ("Limitless Quantum") (collective
Technologies, Services bancaires / financiers, Biotechnologies, Soins de santé et hôpitaux
2026-04-08 11:46 AM EDT | Trenchant Technologies Capital Corp.
Adia Nutrition Strikes Major Partnership with Leading Atlanta Clinic to Launch Groundbreaking Autism Clinical Study
Winter Park, Florida--(Newsfile Corp. - April 8, 2026) - Adia Nutrition, Inc. (OTCQB: ADIA), a leader in regenerative medicine, today announced a strategic partnership with a prominent clinic in Atlanta, Georgia. Adia Labs will serve as the exclusive supplier of regenerative products for the clinic's new Autism Spectrum Disorder (ASD) clinical study. This partnership is a key part of Adia Nutrition's 2026 plan to build solid scientific evidence for regenerative therapies that have the potenti
Soins de santé et hôpitaux, Santé
2026-04-08 8:30 AM EDT | Adia Nutrition Inc.
The Obesity Medicine Association Hosts Obesity Medicine 2026: The Heart of Obesity Care
Denver, Colorado--(Newsfile Corp. - April 8, 2026) - The Obesity Medicine Association (OMA), the nation's oldest medical society dedicated exclusively to obesity treatment, will host its annual conference, Obesity Medicine 2026: The Heart of Obesity Care, April 10-12 in San Diego, California. Bringing together more than 1,500 clinicians, researchers, and industry leaders, the conference highlights the latest science, clinical strategies, and innovations shaping the future of obesity med
Soins de santé et hôpitaux, Santé
2026-04-08 8:00 AM EDT | Obesity Medicine Association
LevelJump Announces Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - April 7, 2026) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company"), a leading provider of teleradiology and diagnostic imaging services, today announced that it intends to complete a non-brokered private placement (the "Offering") of up to 15,000,000 common shares (the "Shares") of the Company at a price of $0.05 per Share, for gross proceeds of up to $750,000. Completion of the Offering is subject to the approval of the TSX Ventu
Soins de santé et hôpitaux, Santé
2026-04-07 6:18 PM EDT | LevelJump Healthcare Corp.
Canadian Ophthalmologists Highlight Seasonal Environmental Risks to Eye Health
Ottawa, Ontario--(Newsfile Corp. - April 7, 2026) - Ophthalmologists across Canada are observing the impact of seasonal environmental exposures — including ultraviolet (UV) radiation, wildfire smoke, and airborne allergens — on patients' ocular health and visual comfort. As these factors intensify during the spring and summer months, the Canadian Ophthalmological Society (COS) is underscoring the importance of awareness and preventive care to reduce both immediate irritation and l
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-07 7:30 AM EDT | Canadian Ophthalmological Society (COS)
Les ophtalmologistes canadiens mettent en garde contre les risques environnementaux saisonniers pour la santé oculaire
Ottawa, Ontario--(Newsfile Corp. - 7 avril 2026) - Partout au pays, les ophtalmologistes constatent les effets des expositions environnementales saisonnières, notamment le rayonnement ultraviolet (UV), la fumée des feux de forêt et les allergènes en suspension dans l'air - sur la santé oculaire et le confort visuel des patients. À mesure que ces facteurs s'intensifient au printemps et à l'été, la Société canadienne d'ophtalmologie (SCO) s
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-07 7:30 AM EDT | Canadian Ophthalmological Society (COS)
TelyRx Holdings Inc. to Commence Trading on the Toronto Stock Exchange Effective April 7, 2026
Clearwater, Florida--(Newsfile Corp. - April 7, 2026) - TelyRx Holdings Inc. (TSX: TELY) ("TelyRx" or the "Company"), a vertically integrated, technology-enabled healthcare and pharmacy services company, today announced that its subordinate voting shares will commence trading on the Toronto Stock Exchange ("TSX") under the ticker symbol "TELY" effective Tuesday, April 7, 2026. This milestone follows the completion of its go-public transaction pursuant to the combination with Apolo V Acquisiti
Soins de santé et hôpitaux, Santé
2026-04-07 7:00 AM EDT | TelyRx
Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets
Northvale, New Jersey--(Newsfile Corp. - April 2, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of methadone hydrochloride 5 mg and 10 mg tablets. Methadone tablets are indicated for the management of severe and persistent pain that requires an opioid analgesic that cannot be adequately treated with alternative o
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-02 8:00 AM EDT | Elite Pharmaceuticals, Inc.
Resverlogix Corp. Announces Issuance of MCTO by ASC
Calgary, Alberta--(Newsfile Corp. - April 2, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announces the issuance of a management cease trade order ("MCTO") by the Alberta Securities Commission (the "ASC") under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"), following an application made by the Company, and first announced on March 17, 2026 (the "Original Announcement"). The MCTO relates to Resverlogix's default on the prescribed deadl
Technologies, Biotechnologies, Soins de santé et hôpitaux
2026-04-02 7:15 AM EDT | Resverlogix Corp.
Adia Nutrition, Inc. Reports Strong Revenue Growth in 2025 Annual Report, Highlighting Transition to Regenerative Medicine and Full SEC Reporting Status
Winter Park, Florida--(Newsfile Corp. - April 1, 2026) - Adia Nutrition, Inc. (OTCQB: ADIA), a leader in regenerative medicine, stem cell therapies, and premium wellness solutions, today announced key highlights from its Form 10-K annual report for the year ended December 31, 2025. The filing marks a pivotal year of operational expansion following the company's successful transition from a dormant shell to an active player in the high-growth regenerative healthcare sector. In 2025, Adi
Soins de santé et hôpitaux, Santé
2026-04-01 10:07 AM EDT | Adia Nutrition Inc.
Envoy Medical Announces First Patients Successfully Reaching 12-Month Endpoint in Pivotal Clinical Trial for Fully Implanted Cochlear Implant
White Bear Lake, Minnesota--(Newsfile Corp. - April 1, 2026) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company pioneering fully implanted hearing solutions, announced that the first three patients implanted in its pivotal clinical trial for the fully implanted Acclaim® cochlear implant have successfully completed their 12-month endpoint visit, marking a key milestone in the study's pr
Biotechnologies, Soins de santé et hôpitaux
2026-04-01 8:00 AM EDT | Envoy Medical, Inc.